Megakaryocytes transfer mitochondria to bone marrow mesenchymal stromal cells to lower platelet activation
Journal of Clinical Investigation · 2025
DOI: 10.1172/jci189801 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2025. Verfasst von Chengjie Gao und 16 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Membrane Biology. Hauptthemen laut MEDLINE: Mesenchymal Stem Cells, Megakaryocytes, Platelet Activation, Mitochondria. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, NCI NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Newly produced platelets acquire a low activation state, but whether the megakaryocyte plays a role in this outcome has not been fully uncovered. Mesenchymal stem cells (MSCs) were previously shown to promote platelet production and lower platelet activation. We found that healthy megakaryocytes transfer mitochondria to MSCs, which is mediated by connexin 43 (Cx43) gap junctions on MSCs and leads to platelets at a low energetic state with increased LYN activation, characteristic of resting platelets with increased LYN activation, characteristic of resting platelets. On the contrary, MSCs have a limited ability to transfer mitochondria to megakaryocytes. Sickle cell disease (SCD) is characterized by hemolytic anemia and results in heightened platelet activation, contributing to numerous disease complications. Platelets in SCD mice and human samples had a heightened energetic state with increased glycolysis. MSC exposure to heme in SCD led to decreased Cx43 expression and a reduced ability to uptake mitochondria from megakaryocytes. This prevented LYN activation in platelets and contributed to increased platelet activation at steady state. Altogether, our findings demonstrate an effect of hemolysis in the microenvironment leading to increased platelet activation in SCD. These findings have the potential to inspire new therapeutic targets to relieve thrombosis-related complications of SCD and other hemolytic conditions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Membrane Biology.
- Laboratory of Stem Cell Biology and Engineering Research.
- Laboratory of Immune Regulation.
- Laboratory of Vascular Inflammation and Thrombosis Research.
- Laboratory of Complement Biology.
- Sickle Cell Clinical Research Program, and.
Förderung
- NHLBI NIH HHS
- NCI NIH HHS
- National Institutes of Health
Zitieren
APA
Gao, C., Dai, Y., Spezza, P. A., Boasiako, P., Tang, A., Rasquinha, G., Zhong, H., Shao, B., Liu, Y., Shi, P. A., Lobo, C. A., An, X., Guo, A., Mitchell, W. B., Manwani, D., Yazdanbakhsh, K., & Mendelson, A. (2025). Megakaryocytes transfer mitochondria to bone marrow mesenchymal stromal cells to lower platelet activation. Journal of Clinical Investigation. https://doi.org/10.1172/jci189801
Vancouver
Gao C, Dai Y, Spezza PA, Boasiako P, Tang A, Rasquinha G, et al. Megakaryocytes transfer mitochondria to bone marrow mesenchymal stromal cells to lower platelet activation. Journal of Clinical Investigation. 2025. doi:10.1172/jci189801
BibTeX
@article{Gao2025,
author = {Gao, Chengjie and Dai, Yitian and Spezza, Paul A and Boasiako, Paul and Tang, Alice and Rasquinha, Giselle and Zhong, Hui and Shao, Bojing and Liu, Yunfeng and Shi, Patricia A and Lobo, Cheryl A and An, Xiuli and Guo, Anqi and Mitchell, William B and Manwani, Deepa and Yazdanbakhsh, Karina and Mendelson, Avital},
title = {Megakaryocytes transfer mitochondria to bone marrow mesenchymal stromal cells to lower platelet activation},
journal = {Journal of Clinical Investigation},
year = {2025},
doi = {10.1172/jci189801}
}
EUVIMED